BIOTRICITY INC

For the period ended Mar 31, 2024. Filed Jun 27, 2024.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Jun 27, 2024

BTCY$0.06+7.1%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Statements of Mezzanine Equity and Stockholders’ Deficiency

Mezzanine Equity · Total Mezzanine Equity · Preferred stock · Common stock and exchangeable common shares · Shares to be Issued · Additional paid in capital · Accumulated other comprehensive (loss) income · Accumulated deficit · Total Stockholders’ Deficiency
	Shares	$	$	Shares	$	Shares	$	Shares	$	$	$	$	$
Balance, March 31, 2023	—	—	—	6,305	7	8,752,510	8,753	3,955	24,999	92,844,478	(152,797)	(112,570,825)	(19,845,385)
Issuance of common shares to adjust for rounding effect of Reverse Split [Note 9]	—	—	—	—	—	20,846	21	—	—	(21)	—	—	—
Issuance of common shares for private placement [Note 9]	—	—	—	—	—	36,897	37	—	—	119,248	—	—	119,285
Issuance of mezzanine equity [Note 9]	330	1,860,554	1,860,554	—	—	—	—	—	—	—	—	—	—
Issuance of warrants for private placement holders [Note 9]	—	—	—	—	—	—	—	—	—	1,137,716	—	—	1,137,716
Issuance of warrants for brokers [Note 9]	—	—	—	—	—	—	—	—	—	141,070	—	—	141,070
Conversion of mezzanine equity into common shares [Note 9]	(65)	(371,634)	(371,634)	—	—	612,062	612	320,321	228,786	353,907	—	—	583,305
Issuance of shares for services [Note 9]	—	—	—	—	—	92,125	92	20,000	15,280	100,755	—	—	116,127
Stock based compensation - ESOP [Note 9]	—	—	—	—	—	—	—	—	—	1,025,930	—	—	1,025,930
Translation adjustment	—	—	—	—	—	—	—	—	—	—	185,175	—	185,175
Net loss before dividends for the period	—	—	—	—	—	—	—	—	—	—	—	(14,094,283)	(14,094,283)
Preferred stock dividends	—	—	—	—	—	—	—	—	—	—	—	(834,677)	(834,677)
Balance, March 31, 2024	265	1,488,920	1,488,920	6,305	7	9,514,440	9,515	344,276	269,065	95,723,083	32,378	(127,499,785)	(31,465,737)

Preferred stock · Common stock and exchangeable common shares · Shares to be Issued · Additional paid in capital · Accumulated other comprehensive (loss) income · Accumulated deficit · Total
	Shares	$	Shares	$	Shares	$	$	$	$	$
Balance, March 31, 2022	7,201	8	8,546,261	8,546	20,638	102,299	91,550,209	(768,656)	(93,037,142)	(2,144,736)
Conversion of convertible notes into common shares [Note 9]	—	—	126,833	127	—	—	843,795	—	—	843,922
Preferred stock purchased back via cash	(896)	(1)	—	—	—	—	(777,174)	—	—	(777,175)
Issuance of shares for services [Note 9]	—	—	22,035	22	—	—	150,396	—	—	150,418
Issuance of warrants for services [Note 9]	—	—	—	—	—	—	232,526	—	—	232,526
Exercise of warrants for cash [Note 9]	—	—	11,966	12	(16,683)	(77,300)	47,514	—	—	(29,774)
Exchange of warrants for promissory notes [Note 9]	—	—	—	—	—	—	(71,768)	—	—	(71,768)
Issuance of shares in lieu of convertible note interest [Note 9]	—	—	45,043	45	—	—	221,351	—	—	221,396
Stock based compensation - ESOP [Note 9]	—	—	—	—	—	—	647,631	—	—	647,631
Cashless exercise of options [Note 9]	—	—	372	1	—	—	(2)	—	—	(1)
Translation adjustment	—	—	—	—	—	—	—	615,859	—	615,859
Net loss before dividends for the year	—	—	—	—	—	—	—	—	(18,658,143)	(18,658,143)
Preferred stock dividends	—	—	—	—	—	—	—	—	(875,540)	(875,540)
Balance, March 31, 2023	6,305	7	8,752,510	8,753	3,955	24,999	92,844,478	(152,797)	(112,570,825)	(19,845,385)

The consolidated statements of mezzanine equity and stockholder’s deficiency share amounts have been retroactively adjusted to account forthe Company’s 1:6 Reverse Split, effective July 3, 2023.

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.